Evidence map›Paper›PMID 27512951›Full record

ArticleCell death & disease2016

Golgi-associated LC3 lipidation requires V-ATPase in noncanonical autophagy.

Ying Gao, Yajun Liu, Liang Hong, Zuolong Yang, Xinran Cai, Xiaoyun Chen, Yuanyuan Fu, Yujie Lin, Weijie Wen, Sitong Li and 6 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. A role for CASM in the repair of damaged Golgi architecture.bioRxiv : the preprint server for biology · 2025
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Mechanisms and roles of membrane-anchored ATG8s.Frontiers in cell and developmental biology · 2025
    Review
  14. Lysosomes' fallback strategies: more than just survival or death.Frontiers in cell and developmental biology · 2025
    Review
  15. Lack of WDFY4 leads to impaired immune response and poor cancer prognosis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
  16. Article
  17. Targeting Lipid Metabolism in Cancer Stem Cells for Anticancer Treatment.International journal of molecular sciences · 2024
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Ying GaoNational and Local United Engineering Lab of Druggability and New Drugs Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Yajun LiuNational and Local United Engineering Lab of Druggability and New Drugs Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Liang HongNational and Local United Engineering Lab of Druggability and New Drugs Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Zuolong YangNational and Local United Engineering Lab of Druggability and New Drugs Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Xinran CaiNational and Local United Engineering Lab of Druggability and New Drugs Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Xiaoyun ChenDepartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Yuanyuan FuNational and Local United Engineering Lab of Druggability and New Drugs Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Yujie LinNational and Local United Engineering Lab of Druggability and New Drugs Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Weijie WenNational and Local United Engineering Lab of Druggability and New Drugs Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Sitong LiNational and Local United Engineering Lab of Druggability and New Drugs Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Xingguo LiuGuangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.
Heqing HuangNational and Local United Engineering Lab of Druggability and New Drugs Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Andreas VogtDepartment of Computational and Systems Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
Peiqing LiuNational and Local United Engineering Lab of Druggability and New Drugs Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Xiao-Ming YinDepartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Min LiNational and Local United Engineering Lab of Druggability and New Drugs Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Sun Yat-sen University · CNChinese Academy of Sciences · CNIndiana University – Purdue University Indianapolis · USIndiana University School of MedicineUniversity of Pittsburgh · US

Funding

Signal integration of the death receptor pathwaysR01CA083817 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YIN, XIAO-MING · 2000 to 2010
$2.1M
The impact of growth modulation of liver carcinogenesisR01CA111456 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YIN, XIAO-MING · 2005 to 2009
$1.4M
High-Content Cell-Based Screening for Modulators of AutophagyR03MH083154 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YIN, XIAO-MING · 2007 to 2007
$25k
NCI NIH HHS R01 CA083817NCI NIH HHS R01 CA111456NIMH NIH HHS R03 MH083154
6 · The paper itself

Abstract

Autophagy is an evolutionarily conserved catabolic process by which cells degrade intracellular proteins and organelles in the lysosomes. Canonical autophagy requires all autophagy proteins (ATGs), whereas noncanonical autophagy is activated by diverse agents in which some of the essential autophagy proteins are dispensable. How noncanonical autophagy is induced and/or inhibited is still largely unclear. In this study, we demonstrated that AMDE-1, a recently identified chemical that can induce canonical autophagy, was able to elicit noncanonical autophagy that is independent of the ULK1 (unc-51-like kinase 1) complex and the Beclin1 complex. AMDE-1-induced noncanonical autophagy could be specifically suppressed by various V-ATPase (vacuolar-type H(+)-ATPase) inhibitors, but not by disturbance of the lysosome function or the intracellular ion redistribution. Similar findings were applicable to a diverse group of stimuli that can induce noncanonical autophagy in a FIP200-independent manner. AMDE-1-induced LC3 lipidation was colocalized with the Golgi complex, and was inhibited by the disturbance of Golgi complex. The integrity of the Golgi complex was also required for multiple other agents to stimulate noncanonical LC3 lipidation. These results suggest that the Golgi complex may serve as a membrane platform for noncanonical autophagy where V-ATPase is a key player. V-ATPase inhibitors could be useful tools for studying noncanonical autophagy.

Indexed as

AutophagyAnimalsAutophagy-Related Protein-1 HomologBeclin-1Enzyme InhibitorsFibroblastsGolgi ApparatusIonophoresLipidsLysosomesMacrolidesMiceMicrotubule-Associated ProteinsModels, BiologicalUbiquitinVacuolar Proton-Translocating ATPasesAutophagy-Related Protein-1 Homologbafilomycin A1Beclin-1Becn1 protein, mouseEnzyme InhibitorsIonophoresLipidsMacrolidesMap1lc3b protein, mouseMicrotubule-Associated ProteinsUbiquitinUlk1 protein, mouseVacuolar Proton-Translocating ATPases

Identifiers

PMID27512951
PMCPMC5108321
OpenAlexW2507922791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.